To include your compound in the COVID-19 Resource Center, submit it here.

Alicaforsen: Phase II data; Phase II for ulcerative colitis, Phase III for Crohn's disease

Results from the first 8 of 12 patients in an open-label U.S. Phase II trial showed nightly

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE